the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Conditions:   Non-small Cell Lung Cancer;   Brain Metastases Intervention:   Drug: Anlotinib Sponsor:   Li-kun Chen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials